Teligent, Inc. Announces Hiring of Chief Legal Officer and Corporate Secretary
Teligent, Inc. (Nasdaq: TLGT) announced the appointment of Philip Yachmetz as Chief Legal Officer and Corporate Secretary, effective July 16, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Teligent, Inc. (Nasdaq: TLGT) announced the appointment of Philip Yachmetz as Chief Legal Officer and Corporate Secretary, effective July 16, 2020. Yachmetz brings extensive experience in the pharmaceutical and healthcare sectors, particularly from his previous roles including Chief Legal and Compliance Officer at Sovereign Medical Services and senior executive at Savient Pharmaceuticals.
In connection with his employment, Teligent's Board granted Yachmetz 23,505 restricted stock units and an option to purchase 36,325 shares at $2.34 each, with vesting scheduled over three years.
Positive
- Appointment of Philip Yachmetz as Chief Legal Officer, which may enhance the company's legal and compliance capabilities.
- Yachmetz's extensive experience in the pharmaceutical sector could lead to stronger governance and strategic initiatives.
Negative
- None.
Details
News Market Reaction – TLGT
The recorded move for TLGT in the trading session of this news was +3.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BUENA, N.J., July 17, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced the hiring of Philip Yachmetz as Chief Legal Officer and Corporate Secretary of the Company, effective July 16, 2020.
Timothy B. Sawyer, President and CEO of the Company, commented, “We are pleased that Phil has agreed to join our Teligent team. Phil’s extensive experience as a general counsel/chief legal and compliance officer with pharmaceutical, biotechnology and healthcare companies will be an excellent addition to our team.”
Most recently, from 2015 through July 2020, Mr. Yachmetz served as Chief Legal and Compliance Officer of Sovereign Medical Services, Inc., a privately held fully integrated community healthcare system company. Prior to his position at Sovereign, Mr. Yachmetz held several senior executive positions at Savient Pharmaceuticals, Inc., a publicly-held specialty biopharmaceutical company from 2004 to 2014, including Co-President, Chief Business Officer, Executive Vice President, General Counsel and Secretary from 2004 to 2014. Mr. Yachmetz holds a J.D. from the California Western School of Law and a B.A. from George Washington University.
Inducement Award
In connection with the hiring of Mr. Yachmetz, in addition to other compensation disclosed in Teligent’s Current Report on Form 8-K, Teligent’s Board of Directors authorized the grant to Mr. Yachmetz of (i) 23,505 restricted stock units; and (ii) a non-qualified stock option to purchase 36,325 shares of Common Stock. The awards are an inducement material to Mr. Yachmetz’s entering into employment with Teligent in accordance with Nasdaq Listing Rule 5635(c)(4). The option has a ten-year term and an exercise price of
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
| Contact: | Damian Finio Teligent, Inc. (856) 336-9117 www.teligent.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.